))
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
Manage episode 435582822 series 3560609
Jacqueline Stone and Oncololgy News Central에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Jacqueline Stone and Oncololgy News Central 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
“I think the antibody-drug conjugates (ADCs) for physicians, and certainly patients too, are a little bit tough to wrap your head around,” says Erika P. Hamilton, MD, the director of breast cancer and gynecologic cancer research at Sarah Cannon Research Institute in Nashville. She discusses how TROP2-targeting ADCs currently fit into practice with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. From how to “choose the right patient for the right treatment at the right time” to important toxicity concerns, Dr. Hamilton shares her “elevator pitch” to patients when it comes to ADCs. “I think a very easy way to really talk about the activity at this point is just the fact that they’re beating naked chemotherapy. So they are performing better than chemotherapy and, for the most part, comparing favorably in terms of side effects for patients as well.”
Dr. Hamilton reported various financial relationships.
Dr. Figlin reported various financial relationships.
130 에피소드
공유
